Drug Trial Radar · NCT06679946
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
700
Planned (sponsor's estimate)
Start
Dec 3, 2024
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
VutrisiranDrug
Vutrisiran administered SC q3M
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Adverse Events (AEs)Time frame: Up to 36 Months
Locations
87 sites in 17 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Phoenix, Arizona
Clinical Trial Site
Beverly Hills, California
Clinical Trial Site
La Jolla, California
Clinical Trial Site
Stanford, California
Clinical Trial Site
Washington D.C., District of Columbia
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Glenview, Illinois
Clinical Trial Site
Indianapolis, Indiana
Clinical Trial Site
Kansas City, Kansas
Clinical Trial Site
Baltimore, Maryland
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
Omaha, Nebraska
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Durham, North Carolina
Clinical Trial Site
Cleveland, Ohio
Clinical Trial Site
Columbus, Ohio
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Nashville, Tennessee
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Salt Lake City, Utah
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Córdoba, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
Rosario, Argentina
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Aalst, Belgium
Clinical Trial Site
Anderlecht, Belgium
Clinical Trial Site
Dendermonde, Belgium
Clinical Trial Site
Ghent, Belgium
Clinical Trial Site
Hasselt, Belgium
Clinical Trial Site
Leuven, Belgium
Clinical Trial Site
Liège, Belgium
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.